drugset / Trial / NCT00225251

Wellbutrin XL for Dysthymic Disorder

NCT00225251

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a ten-week, double-blind study of Wellbutrin XL in outpatients with dysthymic disorder, a form of low-grade chronic depression. We hypothesize that patients taking Wellbutrin XL will show greater improvement in depression symptoms and psychosocial functioning than patients taking placebo.

Timeline

Start
2004-11
Primary completion
2008-05
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg
Subject Bupropion Small molecule 450 mg

Indications